JonesTrading has commenced coverage on shares of Evaxion A/S (NASDAQ: EVAX), issuing a buy rating and establishing a price target of $10.00. This announcement came in a research report published on the morning of March 5, 2024, according to a report by Benzinga.
In addition to JonesTrading’s optimistic outlook, several other analysts have shared their assessments of Evaxion’s stock. On the same day, Lake Street Capital reduced its price target from $11.00 to $9.00 while maintaining a buy rating. Earlier, on February 19, Maxim Group also initiated coverage on Evaxion with a buy rating and a price target of $10.00. Meanwhile, HC Wainwright reaffirmed a buy rating with a target of $16.00 on the same day that JonesTrading published its report. Contrarily, Weiss Ratings assigned a “sell (d-)” rating on January 9, 2024.
Currently, five analysts have rated Evaxion with a buy recommendation, while one has issued a sell rating. According to MarketBeat.com, the stock enjoys an average rating of “Moderate Buy” and an average price target of $11.00.
Recent Performance and Earnings
On March 5, 2024, Evaxion reported its quarterly earnings, showing an earnings per share (EPS) of $0.30. Analysts expect the company to post an EPS of -0.15 for the current year, indicating a challenging period ahead. The market response to the latest earnings report reflects investor sentiment regarding Evaxion’s future prospects.
Institutional Investment Activity
Recent activity among institutional investors has seen notable changes in share ownership. Wesbanco Bank Inc. acquired a new stake in Evaxion, valued at $48,000, during the fourth quarter. Similarly, Northwestern Mutual Wealth Management Co. and SmartHarvest Portfolios LLC made new investments worth $38,000 and $72,000 respectively. Institutional investors now control approximately 11.04% of Evaxion’s stock.
Evaxion A/S is a clinical-stage biotechnology firm based in Copenhagen, Denmark, with operations extending into the United States. The company focuses on developing immunotherapies and vaccines using its proprietary AI-driven computational immunology platform. This innovative approach utilizes machine learning and deep learning to identify and optimize antigen targets for cancer vaccines and infectious disease prophylactics. The core of Evaxion’s business lies in its AI platform, which analyzes extensive datasets of genomic, proteomic, and immunological information to predict immune-stimulating epitopes.
As Evaxion continues to navigate the complexities of the biotechnology landscape, the recent ratings and institutional investments may play a significant role in shaping its market trajectory.
